PLX Protalix BioTherapeutics, Inc.

8-K Current Report

Filed: March 9, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Protalix BioTherapeutics, Inc. (PLX) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• EC approved new E4W (every-4-weeks) 2 mg/kg dosing regimen for Elfabrio in EU — expands label beyond prior dosing schedule
• Label expansion targets stable Fabry disease patients on ERT, potentially broadening addressable patient pool and improving convenience vs. more frequent dosing

+2 more insights

Other Protalix BioTherapeutics, Inc. 8-K Filings

8-K Mar 18, 2026

Get deeper insights on Protalix BioTherapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.